Quick Answer
Protagenic Therapeutics, Inc.new reported R&D Expense of $3.84 million for fiscal year 2024.
Protagenic Therapeutics, Inc.new R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $3.84M | +25.5% |
| 2023 | $3.06M | +92.8% |
| 2022 | $1.59M | +39.8% |
| 2021 | $1.14M | +62.4% |
| 2020 | $699.8K | -13.4% |
| 2019 | $807.9K | -8.3% |
| 2018 | $881.2K | +22.8% |
| 2017 | $717.5K | +71.7% |
| 2016 | $417.9K | -8.4% |
| 2015 | $456.3K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $153.8K | +14.3% | -43.7% |
| September 30, 2025 | $273.2K | +1510.6% | -69.0% |
| March 31, 2025 | $880.4K | -39.7% | +554.2% |
| December 31, 2024 | $134.6K | — | +693.3% |
| September 30, 2024 | $17.0K | -98.5% | -98.6% |
| June 30, 2024 | $1.20M | +78.3% | -18.1% |
| March 31, 2024 | $1.46M | +319.7% | +30.0% |
| September 30, 2023 | $1.12M | +124.2% | +67.5% |
- Protagenic Therapeutics, Inc.new showed an increase of +25.5% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2024 period, Protagenic Therapeutics, Inc.new’s r&d expense has grown by 742.7% (from $456.3 thousand to $3.84 million).
- The most recent figure is from Protagenic Therapeutics, Inc.new’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: